AcelRx Pharmaceuticals In... (ACRX)
NASDAQ: ACRX
· Real-Time Price · USD
0.86
0.06 (7.50%)
At close: Jan 09, 2024, 10:00 PM
AcelRx Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 27K | -370K | n/a | n/a | n/a | 281K | 117K | 253K | n/a | 252K | 507K | 570K | 442K | 2K | 1.86M | 443K | 511K |
Cost of Revenue | n/a | n/a | 2.6M | n/a | n/a | n/a | n/a | n/a | 1.55M | 1.05M | 362K | 569K | 876K | 784K | 1.23M | 439K | 1.04M | 1.04M |
Gross Profit | n/a | n/a | 2.23M | n/a | n/a | n/a | n/a | 117K | -1.3M | -1.05M | -110K | -62K | -306K | -342K | -1.23M | 1.42M | -597K | -529K |
Operating Income | -3.69M | -2.92M | -3M | 1.41M | -4.27M | -4.24M | -9.79M | -3.31M | -3.97M | -5.33M | -3.73M | -6.63M | -13.57M | -8.99M | -8.18M | -8.63M | -10.02M | -9.14M |
Interest Income | n/a | n/a | -8.25M | n/a | n/a | n/a | -227K | 1.89M | 843K | 5.51M | 137K | 140K | 514K | 711K | 725K | 796K | 799K | 858K |
Pretax Income | -3.49M | -2.59M | -1.87M | 2M | -3.83M | -3.95M | -4.51M | -1.42M | -4.42M | 64K | -7.49M | -6.74M | 70.67M | -8.67M | -7.92M | -8.38M | -9.85M | -8.96M |
Net Income | -3.49M | -2.59M | -1.87M | -3.35M | -3.83M | -3.95M | -4.52M | -1.36M | -4.37M | 5.34M | -7.48M | -6.75M | 70.66M | -8.67M | -7.92M | -8.38M | -9.85M | -8.96M |
Selling & General & Admin | 2.19M | 1.77M | 665K | 1.7M | 2.36M | 2.8M | 2.79M | 2.25M | 2.67M | 4.28M | 3.69M | 5.26M | 6.82M | 7.34M | 9.49M | 8.64M | 8.69M | 7.64M |
Research & Development | 1.5M | 1.17M | 2.94M | 2.05M | 1.91M | 1.43M | 1.77M | 1.18M | 1.55M | 1.05M | 1.03M | 1.31M | 1.54M | 1.31M | 674K | 1.42M | 724K | 969K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 4.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 3.69M | 2.94M | 3.61M | 3.75M | 4.27M | 4.24M | 4.56M | 3.43M | 4.22M | 5.33M | 7.28M | 6.57M | 8.37M | 8.65M | 9.4M | 10.06M | 9.42M | 8.61M |
Interest Expense | n/a | n/a | -969K | n/a | -213K | -181K | n/a | n/a | 456K | 119K | 189K | 247K | 327K | 390K | 467K | 538K | 630K | 672K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.69M | 2.94M | 6.21M | 3.75M | 4.27M | 4.24M | 4.56M | 3.43M | 4.22M | 5.33M | 7.64M | 7.14M | 9.24M | 9.44M | 12.02M | 10.49M | 10.46M | 9.65M |
Income Tax Expense | n/a | n/a | 5.27M | n/a | n/a | n/a | -5K | 2K | 3K | -5.27M | -1K | 11K | 3K | -321K | 467K | n/a | 5K | n/a |
Shares Outstanding (Basic) | 34.53M | 20.04M | 16.26M | 16.36M | 14.26M | 14.26M | 12.67M | 16.76M | 10.92M | 10.89M | 7.41M | 7.38M | 7.36M | 7.28M | 6.38M | 5.96M | 5.96M | 5.66M |
Shares Outstanding (Diluted) | 34.53M | 20.04M | 16.26M | 16.36M | 14.26M | 14.26M | 12.67M | 16.76M | 10.92M | 10.89M | 7.41M | 7.38M | 7.36M | 7.28M | 6.38M | 5.96M | 5.96M | 5.66M |
EPS (Basic) | -0.1 | -0.11 | -0.27 | -0.17 | -0.15 | -0.28 | -1.15 | -0.08 | -0.4 | 0.49 | -1.01 | -0.94 | 9.60 | -1.19 | -1.2 | -1.4 | -1.6 | -1.6 |
EPS (Diluted) | -0.1 | -0.11 | -0.27 | -0.17 | -0.15 | -0.28 | -1.15 | -0.08 | -0.4 | 0.49 | -1 | -0.94 | 9.60 | -1.19 | -1.2 | -1.4 | -1.6 | -1.6 |
EBITDA | -3.69M | -2.92M | -3M | -3.75M | -4.27M | -4.24M | -4.51M | -1.42M | -3.92M | 445K | -6.91M | -6.07M | 76.36M | -7.86M | -6.99M | -7.35M | -8.64M | -7.83M |
EBIT | n/a | n/a | -183K | n/a | n/a | n/a | n/a | -3.31M | -3.97M | 183K | -3.64M | -6.49M | 70.99M | -8.28M | 9.53M | -7.84M | -9.22M | -8.28M |
Depreciation & Amortization | n/a | n/a | -2.2M | n/a | n/a | n/a | -2.2M | 1.89M | 49K | 262K | 184K | 424K | 461K | 420K | 461K | 483K | 579K | 450K |